Slide 1: EVO301 Top-Line Results from Phase 2a Trial in Moderate-to-Severe Atopic Dermatitis
EVO301 Top-Line Results from Phase 2a Trial in Moderate-to-Severe Atopic Dermatitis February 10, 2026 © Evommune, Inc.
Slide 2: Forward-Looking Statements
Forward-Looking Statements © Evommune, Inc. Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "exp
Slide 3: Agenda and Speakers
Luis Peña Founder, President & CEO Mark Jackson, MD SVP, Clinical Development Agenda and Speakers Introduction Luis Peña Founder, President & CEO IL-18 Development Program Mark Jackson, MD SVP, Clinical Development EVO301 Phase 2a Data Mark Jackson, MD SVP, Clinical Development Closing Remarks Luis
Slide 4: Our Mission-Driven Approach to Treating Immune-Mediated Diseases
5v Our Mission-Driven Approach to Treating Immune-Mediated Diseases © Evommune, Inc. Two Phase 2 Programs with Diverse Approaches Targeting Heterogeneous Diseases EVO756: Oral Therapy Targeting Mast Cells and Sensory Neurons EVO301: IL-18 Blockade for Multi-Pathway Immunomodulation Address critical
Slide 5: Our Inflammation Portfolio and the Role of EVO301
Our Inflammation Portfolio and the Role of EVO301 © Evommune, Inc. Program / Target Indication Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone EVO756 MRGPRX2 Chronic Spontaneous Urticaria Phase 2b Data (H1 2026) Atopic Dermatitis Phase 2b Data (H2 2026) Other Indications Phase 2 Trial
Slide 6: IL-18 Drives Various Innate and Adaptive Immune Processes
IL-18 Drives Various Innate and Adaptive Immune Processes Related to Infection, Inflammation and Autoimmunity © Evommune, Inc. PAMPs: Pathogen-associated molecular patterns; DAMPs: Damage-associated molecular patterns Chronic Inflammation Tissue Pathophysiology Clinical Manifestations Inflammatory I
Slide 7: EVO301: Long-Acting IL-18 Neutralizer Designed for Tissue Targeting
EVO301: Long-Acting IL-18 Neutralizer Designed for Tissue Targeting SAFA* and IL-18BP fused via peptide linker for extended neutralization of IL-18 activity © Evommune, Inc. SAFA - Anti-Serum Albumin Fab-Associated. HAS – Human Serum Albumin SAFABODY™ is a trademark of AprilBio Co., Ltd. SAFAbody™ P
Slide 8: IL-18 Impacts Multiple Inflammatory Pathways that Drive Atopic Dermatitis
Biologic Pathway Adaptive Inflammation Innate Inflammation Skin Barrier (IL-22) TH2 TH1 TH17 IL-18 IL-4 / -13 IL-18 Impacts Multiple Inflammatory Pathways that Drive Atopic Dermatitis © Evommune, Inc. Green = impacts biological pathway; Red = negative effect. IL-18 modulation of broader immunologica
Slide 9: EVO301 Achieved the Primary Endpoint
EVO301 Achieved the Primary Endpoint Phase 2a Proof-of-Concept Trial in Moderate-to-Severe Atopic Dermatitis Highly statistically significant EASI reductions at weeks 4, 8, and 12 versus placebo 34% and 33% placebo adjusted improvement in EASI at week 8 and 12, respectively 23% of patients achieved
Slide 10: EVO301 Phase 2a Proof of Concept Trial Design
EVO301 Phase 2a Proof of Concept Trial Design © Evommune, Inc. EASI = Eczema Area and Severity Index; vIGA = Validated Investigator Global Assessment; BSA = Body Surface Area; BL = Baseline; PBO = Placebo Screening Randomization 2 Active : 1 PBO End of Trial BL W12 W4 Adults with Moderate-to-Severe
Slide 11: Disposition, Baseline Demographics and Disease Characteristics
Disposition, Baseline Demographics and Disease Characteristics © Evommune, Inc. Note: Numbers in parentheses are standard deviations. BMI: body mass index, EASI: Eczema Area and Severity Index, IGA: Investigator’s global assessment, NRS: numeric rating score, BSA: body surface area, SD: standard dev
Slide 12: Phase 2a Trial in AD Met Primary Outcome Measure (Bayesian)
Phase 2a Trial in AD Met Primary Outcome Measure (Bayesian) EASI: Eczema Area and Severity Index, SD: standard deviation, HPD: high posterior density % Change in EASI at Week 12: Protocol Success Criterion Met Statistic EVO301 versus Placebo Success Criterion: Posterior Probability of Difference < -
Slide 13: Phase 2a Trial in AD Demonstrated Statistically Significant Efficacy Across Time Points
Phase 2a Trial in AD Demonstrated Statistically Significant Efficacy Across Time Points EASI: Eczema Area and Severity Index, LS mean: least squares mean, SE: standard error, CI: confidence interval % Change in EASI by Study Visit Visit EVO301 Placebo Placebo-adjusted Change p-value Week 4 -41 -18 -
Slide 14: Statistically Significant Efficacy Across Time Points: % Change in EASI
Week 2 Phase 2a Trial in AD Demonstrated Statistically Significant Efficacy Across Time Points © Evommune, Inc. Week 0 Week 4 Week 8 Week 12 % Average Change in EASI ↓ Dosed at Weeks 0 and 4 Placebo EVO301 * * % Change in EASI by Study Visit *p<0.01 ↓ % Average change in EASI is LS Mean -22 -18 -16
Slide 15: Two Doses of EVO301 Comparable to Marketed Biologics at 16 Weeks
IL-18 IL-31 IL-13 IL-4 / IL-13 Two Doses of EVO301 Demonstrated Comparable Activity at 12 Weeks to Dose-Optimized Marketed Biologics at 16 Weeks © Evommune, Inc. For illustrative purposes only. Not a head-to-head comparison. Differences exist between trial designs and study characteristics, and caut
Slide 16: Early Clinical Signal in vIGA 0/1 Response
↑ Week 0 ↑ Week 4 Week 8 Week 12 vIGA Response Phase 2a Trial in AD: Early Clinical Signal in vIGA 0/1 Response © Evommune, Inc. vIGA: Validated Investigator’s Global Assessment Visit EVO301 Placebo Week 4 4.2% 0% Week 8 12.5% 0% Week 12 22.9% 0% vIGA Response (≥2-pt improvement and a score of 0 or
Slide 17: Additional Endpoints and Target Engagement
Additional Endpoints and Target Engagement © Evommune, Inc. Full Detailed Results Will Be Presented at a Future Scientific Conference PK and target engagement data continue to support a Q4 week dosing regimen Corresponding reductions in secondary endpoints Corresponding reduction of key Th2 associat
Slide 18: Safety Summary: EVO301 Was Well Tolerated
Safety Summary Over 12 Week Trial Period EVO301 Was Well Tolerated © Evommune, Inc. No Clinically Significant Lab Abnormalities. No Conjunctivitis Reported (as is Common with Other Biologics in AD) EVO301 Placebo Total N=48 N=22 N=70 Patients with ≥1 Adverse Event (AE) 30 (62.5%) 16 (72.7%) 46 (65.7
Slide 19: Atopic Dermatitis: Large and Growing Market
Atopic Dermatitis: Large and Growing Market Expansion of AD Market Outpacing That of Psoriasis © Evommune, Inc. Per Evaluate Pharma (May represent projections and not actual sales); “Year 1” for AD represents 2017 (year of Dupixent launch); “Year 1” for psoriasis represents 2004 (year of Enbrel laun
Slide 20: Summary and Path Forward to Phase 2b and Beyond
Summary and Path Forward to Phase 2b and Beyond © Evommune, Inc. IL-18 modulation of broader immunological cascades beyond Th2 is a key differentiator in AD EVO301 provides unique approach to IL-18 targeting, as a long-acting fusion protein consisting of a binding protein and an anti-serum albumin F
Slide 21: With Two Clinically Validated Programs, Evommune Continues to Deliver on our Strategy
With Two Clinically Validated Programs, Evommune Continues to Deliver on our Strategy © Evommune, Inc. Program / Target Indication Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone EVO756 MRGPRX2 Chronic Spontaneous Urticaria Phase 2b Data (H1 2026) Atopic Dermatitis Phase 2b Data (H2 2
Slide 22: Q&A
Q&A © Evommune, Inc.
Slide 23: Appendix
Appendix 23 ©£vommune, Inc. 3 evommune
Slide 24: Moderate-to-Severe Atopic Dermatitis: Prevalent, Impactful, and Underserved
Moderate-to-Severe Atopic Dermatitis: Heterogenous Disease that is Prevalent, Impactful, and Underserved © Evommune, Inc. Source: Habif’s Clinical Dermatology: A Color Guide to Diagnosis and Therapy. National Eczema Association (accessed 2026), Luckhaupt, et al. (2013). Dupixent Prescribing Informat
Slide 25: IL-18 Shows Similar Efficacy to IL-4 targeting Agents in vivo
IL-18 Shows Similar Efficacy to IL-4 targeting Agents in vivo Study design: SK-1 hairless mice were sensitized with 100 ul of 3% oxazolone on Day 0. On Day 7, mice were challenged with 100ul of 0.3% oxazolone on the back, three times a week. Cumulative score = sum of score (0-4) for erythema, scalin
Slide 26: Phase 2a Trial in AD: Primary Outcome Measure (Bayesian)
Phase 2a Trial in AD: Primary Outcome Measure (Bayesian) Posterior Distribution Curves © Evommune, Inc. % Change in EASI by Study Visit (Placebo Adjusted) EASI: Eczema Area and Severity Index -8 Week 12 Week 2 Week 4 Week 8 -32.5 -28.2 -21.5 -7.1 % Change in EASI 0 -20 -40 Density 0.06 – 0.04 – 0.02
Slide 27: IL-18 Biology Extends Beyond Atopic Dermatitis
IL-18 Biology Extends Beyond Atopic Dermatitis, Supporting Multi-Indication Value Creation for EVO301 © Evommune, Inc. Neurologic Multiple Sclerosis • Myasthenia Gravis • Multi-Organ • Systemic Lupus Erythematosus • Dermatomyositis & Polymyositis Other • Adult Onset Still Disease • Rheumatoid Arthri